Traders should monitor the June 18, 2026 FDA decision as a key catalyst; the strong cash position and reduced burn rate improve the company's runway and reduce near-term dilution risk, while the GSK partnership de-risks commercialization. The sharp improvement in profitability and revenue, driven by collaboration inflows, suggests improved financial sustainability pending regulatory outcome.
Price Chart
Executive Summary
Spero Therapeutics reported a significant turnaround in financial performance for Q4 and full-year 2025, driven by a 177% YoY revenue increase to $41.3M in the quarter, primarily from collaboration payments with GSK and Pfizer, while R&D expenses dropped 80% due to reduced trial activity. The company also announced that the FDA set a PDUFA date of June 18, 2026, for tebipenem HBr, an investigational oral antibiotic for cUTI, with cash reserves of $40.3M expected to fund operations into 2028.
Key Financial Metrics
Key Facts
- Net income of $31.5M in Q4 2025 vs. net loss of $(20.9)M in Q4 2024
- Total revenue of $41.3M in Q4 2025, up from $15.0M in Q4 2024 (175% YoY growth)
- Full-year 2025 revenue of $66.8M vs. $48.0M in 2024
- R&D expenses fell to $5.6M in Q4 2025 from $28.8M in Q4 2024 due to completion of the PIVOT-PO trial
- FDA set PDUFA date of June 18, 2026, for tebipenem HBr NDA resubmission for cUTI
- Cash and equivalents: $40.3M as of Dec 31, 2025, expected to fund operations into 2028
- Received $25M milestone payment from GSK in Q1 2026 for NDA resubmission
Financial Impact
Revenue increased by $18.8M annually and $26.3M quarterly, while R&D costs decreased by $58.3M annually, leading to a $77.1M improvement in net income year-over-year
Risk Factors
- FDA approval of tebipenem HBr is not guaranteed and could be delayed or denied
- Future revenue depends heavily on milestone and collaboration payments, which are non-recurring
- Commercial success depends on GSK's execution, over which Spero has limited control
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263404 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | EFFECT | $1.13 $1.13 | · 0.00% | ▼ −0.34% | $1.19 (−5.31%) |
Aug 28, 2026 4w ago | 8-K | $1.22 $1.19 | ▲ +2.46% | ▲ +2.32% | $1.19 (+2.46%) |
Aug 28, 2026 5w ago | S-3 | $1.22 $1.19 | ▲ +2.46% | ▲ +2.32% | $1.19 (+2.46%) |
Aug 12, 2026 7w ago | Press Release | $1.24 $1.22 | ▼ −1.61% | ▲ +0.35% | $1.19 (−4.03%) |
Jul 14, 2026 11w ago | 8-K | $1.70 $1.44 | ▼ −15.29% | ▼ −14.00% | $1.19 (−30.00%) |
Jul 14, 2026 11w ago | Press Release | $1.70 $1.44 | ▼ −15.29% | ▼ −14.00% | $1.19 (−30.00%) |
Jun 25, 2026 14w ago | 8-K | $2.26 $2.20 | ▼ −2.65% | ▼ −4.82% | $1.19 (−47.35%) |
Jun 22, 2026 14w ago | 8-K | $2.15 $2.26 | ▲ +5.12% | ▲ +4.10% | $1.19 (−44.65%) |
Jun 17, 2026 15w ago | Press Release | $2.11 $2.10 | ▼ −0.47% | ▲ +0.57% | $1.19 (−43.60%) |
May 13, 2026 20w ago | 8-K | $2.76 $2.69 | ▼ −2.54% | ▼ −1.82% | $1.19 (−56.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access